This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Chu, F. Articles by O'Brian, C. A. Search for Related Content PubMed PubMed Citation Articles by Chu, F. Articles by O'Brian, C. A.

Identification of an Inactivating Cysteine Switch in Protein Kinase C, a Rational Target for the Design of Protein Kinase C–Inhibitory Cancer Therapeutics

Departments of ¹ Cancer Biology and ² Molecular Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas

Requests for reprints: Catherine A. O'Brian, Department of Cancer Biology, M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 173, Houston, TX 77030. Phone: 713-792-7969; E-mail: cobrian{at}mdanderson.org.

Critical roles played by some protein kinases in neoplastic transformation and progression provide a rationale for developing selective, small-molecule kinase inhibitors as antineoplastic drugs. Protein kinase C (PKC) is a rational target for cancer therapy, because it is oncogenic and prometastatic in transgenic mouse models. PKC is activated by sn-1,2-diacylglycerol (DAG). Attempts to develop selective PKC inhibitors that block activation by DAG or compete with ATP have not yet met with success, suggesting a need for new strategies. We previously reported that cystamine and a metabolic cystine precursor inactivate PKC in cells in a thiol-reversible manner. In this report, we first determined that PKC became resistant to inactivation by disulfides when Cys⁴⁵² was replaced with alanine by site-specific mutagenesis of human PKC or a constitutively active PKC mutant. These results showed that the disulfides inactivated PKC by thiol-disulfide exchange, either upon Cys⁴⁵² S-thiolation or by rearrangement to an intra-protein disulfide. Mass spectrometric analysis of peptide digests of cystamine-inactivated, carbamidomethylated PKC detected a peptide S-cysteaminylated at Cys⁴⁵², indicating that Cys⁴⁵² S-cysteaminylation is a stable modification. Furthermore, PKC inactivation by N-ethylmaleimide was Cys⁴⁵² dependent, providing corroborative evidence that PKC inhibitors can be designed by targeting Cys⁴⁵² with small molecules that stably modify the residue. Cys⁴⁵² is an active site residue that is conserved in only 11 human protein kinase genes. Therefore, the PKC-inactivating Cys⁴⁵² switch is a rational target for the design of antineoplastic drugs that selectively inhibit PKC.